Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT001 Phase II dose-finding study in amyotrophic lateral sclerosis
ChiCTR2600132186Phase 2Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Sep 2026
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ALT001 in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Change from baseline in ALSFRS-R score at Week 24 of the double-blind period. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ALT001
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ChiCTR2600132186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132186.